7th India-Japan medical product regulatory symposium held at New Delhi
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Submission based on results from pivotal phase III trial showing all primary endpoints met
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
US FDA approval based on NEURO-TTRansform Phase III results
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia
The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information
Subscribe To Our Newsletter & Stay Updated